Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure
Adenosine A1 receptors (A1R) are a potential target for cardiac injury treatment due to their cardioprotective/antihypertrophic actions, but drug development has been hampered by on-target side effects such as bradycardia and altered renal hemodynamics. Biased agonism has emerged as an attractive me...
Main Authors: | Patricia Rueda, Jon Merlin, Stefano Chimenti, Michel Feletou, Jerome Paysant, Paul J. White, Arthur Christopoulos, Patrick M. Sexton, Roger J. Summers, William N. Charman, Lauren T. May, Christopher J. Langmead |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.628060/full |
Similar Items
-
Adenosine Receptor Agonists
by: Markus Wallner, et al.
Published: (2019-01-01) -
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview
by: Diego Dal Ben, et al.
Published: (2019-10-01) -
Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists
by: Sara Bar-Yehuda, et al.
Published: (2001-01-01) -
A1 Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?
by: Fabrizio Vincenzi, et al.
Published: (2020-12-01) -
Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases
by: Wiwin Is Effendi, et al.
Published: (2020-03-01)